Clinical trials: Cognitively Normal
Frontotemporal Lobar Degeneration, Alzheimer Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched…
- Conditions
- Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
- Trial name
- NCT05456503
- Testing
- [18F]-PI-2620
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Alzheimer Disease, Neurofibrillary Tangle
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's…
- Trial name
- NCT07115238
- Testing
- XTR006
- Where
- China
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neurotypical, Cognitively Normal
Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan
This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules.
- Trial name
- NCT06127667
- Testing
- aerobic exercise
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Glioma, Fear of Cancer
FearLess in Cognitively Intact Patients With Glioma
This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.
- Trial name
- FearLess (NCT05604365)
- Testing
- FearLess Intervention
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Alzheimer's Disease
Effects of Simvastatin on Biomarkers
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.
- Trial name
- SimBio (NCT01142336)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Washington
Genetic Predisposition to Disease, Healthy Volunteers
This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults
This study consists of two study parts (Part I and Part II) conducted under a single IRB approval. Individuals that participated in Part I of the study were invited to participate in Part II of the study.
- Trial name
- NCT05386914
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Alzheimer Disease
The Sleep Amyloid, Slow WAve Race and Ethnicity Study
African-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites.
- Trial name
- Sleep AWARE (NCT03814603)
- Testing
- PET-MR Scan, PiB
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Sleep Disordered Breathing, Alzheimer's Disease
Sleep, Aging and Risk for Alzheimer's Disease
Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial…
- Trial name
- SARA (NCT01962779)
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- 2 sites in United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer's Disease, Mild Cognitive Impairment
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
This is a cross-sectional and longitudinal study to evaluate the clinical utility of [18F]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD)…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT02656498
- Testing
- [18F]THK-5351
- Where
- 2 sites in South Korea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Jae Seung Kim
Alzheimer Disease, Family Members
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Trial name
- NCT05776641
- Testing
- GENUS
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Aging, Cognitive Aging
Music Improvisation Training on Cognitive Function in Older Adults
This project will study the effects and mechanisms of a music improvisation training intervention on self-regulation of older adults with and without MCI.
- Conditions
- Aging, Cognitive Aging, Cognitive Impairment, Cognitive Training
- Trial name
- Music Training (NCT06721390)
- Testing
- Piano Improvisation, Music Listening
- Where
- United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Hearing Impaired
Brain and Cognitive Changes After Reasoning or Physical Training in Cognitively Normal Seniors
Seniors 65 years of age and older represent one of the fastest growing segments of society with the population doubling within the next 25 years with dramatic rates of mental decline, costing society billions of dollars each…
- Trial name
- NCT00977418
- Testing
- SMART- Strategic Memory and Reasoning Training, Physical Exercise
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Dallas
Alzheimer's Disease
Biomarker Study for Alzheimer's Disease
The study aims to identify immune biomarkers in peripheral blood for identifying Alzheimer's disease (AD). Blood samples from subjects with AD will be compared to age-matched controls without cognitive symptoms, as well as…
- Trial name
- BiomarkerAD (NCT02472899)
- Testing
- Blood sample
- Where
- Israel
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Beersheva Mental Health Center
Alzheimer Disease
Plasma P-tau2017 and Quantitative Amyloid PET Imaging
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
- Trial name
- NCT05164536
- Testing
- Amyvid
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Invicro
Early Onset Alzheimer Disease, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- LEADS (NCT03507257)
- Testing
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer's Disease
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
This study will evaluate the performance characteristics of a novel [18F] amyloid detection ligand (18F]-AV-45) with respect to its ability to distinguish patients with clinically-diagnosed probable Alzheimer's disease from…
- Trial name
- NCT00855868
- Testing
- florbetapir F 18, [11C]-PIB
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals